Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine

Headache - Tập 44 Số 5 - Trang 414-425 - 2004
David W. Dodick1, Richard B. Lipton2, Vincent T. Martin3, Vasilios Papademetriou4, Wayne D. Rosamond5, Antoinette MaassenVanDenBrink6, Hassan Loutfi7, K.M.A. Welch8, Peter J. Goadsby9, Steven R. Hahn2, Susan Hutchinson10, David B. Matchar11, Stephen D. Silberstein12, Timothy R. Smith13, R. Allan Purdy14, Jane Saiers15
1Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
2Yeshiva University
3University of Cincinnati
4Georgetown University
5University of North Carolina at Chapel Hill
6Erasmus University, Rotterdam
7Mayo Clinic, Scottsdale, AZ
8University of Kansas
9University College London
10University of California, at Irvine#TAB#
11Duke University
12Jefferson Headache Center
13Ryan Headache Center
14Dalhousie University#TAB#
15WriteMedicine, Inc.

Tóm tắt

Background.—Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan‐associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine.Objective.—To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice.Participants.—The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology.Evidence and Consensus Process.—An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow‐up meetings were held by telephone.Conclusions.—(1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk‐benefit profile of triptans favors their use in the absence of contraindications.

Từ khóa


Tài liệu tham khảo

10.1046/j.1526-4610.2001.041007646.x

10.1001/archneur.57.3.418

10.1056/NEJMra010917

10.1046/j.1526-4610.2001.041007638.x

Matchar DB, 2000, Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks, Neurology, 54

10.1016/S0140-6736(01)06711-3

10.1111/j.1526-4610.1999.00006.x

10.1046/j.1526-4610.2000.00091.x

10.1212/01.WNL.0000110312.36809.7F

Practice guidelines: official AAN practice statements. Available at:http://www.aan.com/public/practiceguidelines/list.htm. Accessed July 20 2002.

10.1046/j.1468-2982.2000.00041.x

10.1159/000026233

10.1212/WNL.54.1.156

10.1046/j.1468-2982.2002.00300.x

10.1001/archneur.1996.00550110072014

10.1177/0333102497017S1806

10.1046/j.1526-4610.1998.3810748.x

10.1046/j.1526-4610.1998.3804281.x

OlivaA.HFD‐120 FDA Medical Review of New Drug Application 21‐006;1999.

10.1046/j.1526-4610.2001.01082.x

10.1212/WNL.49.6.1485

10.1046/j.1526-4610.1997.3710640.x

10.1046/j.1526-4610.1998.3803184.x

Sargent J, 1995, Oral sumatriptan is effective and well‐tolerated for the acute treatment of migraine: results of a multicenter study, Neurology, 45, S10

10.1159/000052131

10.1046/j.1468-2982.1999.019004223.x

10.1111/j.1468-2982.2000.00116.x

10.1046/j.1526-4610.2001.111006264.x

10.1046/j.1526-4610.1998.3803173.x

10.1046/j.1468-2982.2000.00066.x

Adverse Event Reporting System. Data on file.2002.Available upon request from corresponding author D Dodick.

Zolmitriptan[prescribing information]. Wilmington DE :AstraZeneca;1999.

Rizatriptan[prescribing information]. Whitehouse Station NJ :Merck;1999.

Sumatriptan Tablets[prescribing information]. Research Triangle Park NC :GlaxoSmithKline;2001.

Naratriptan[prescribing information]. Research Triangle Park NC :GlaxoSmithKline;2001.

Almotriptan[prescribing information]. Pharmacia;2001.

10.1017/S0317167100000147

10.1016/0014-2999(89)90184-2

10.1016/0014-2999(93)90995-T

10.1016/S0014-2999(00)00712-3

Longmore J, 1997, Comparison of the vasoconstrictor properties of the 5‐HT1B/1D receptors agonists rizatriptan and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols, Funct Neurol, 12, 3

10.1212/WNL.55.10.1524

10.1097/00005344-199808000-00008

10.1111/j.1365-2125.1996.tb00005.x

10.1046/j.1526-4610.1998.3804288.x

10.1046/j.1468-2982.1999.019007651.x

MacIntyre PD, 1992, The effect of i.v. sumatriptan, a selective 5‐HT1 receptor agonist, on central haemodynamics and the coronary circulation, Br J Clin Pharmacol, 34, 541

10.1161/01.CIR.87.2.401

10.1097/00005344-199907000-00015

10.1016/S0009-9236(99)70057-3

10.1111/j.1468-2982.2003.00713.x

10.1016/S0140-6736(95)90205-8

10.1212/WNL.48.6.1542

10.1056/NEJM198103263041306

10.1046/j.1526-4610.1996.3605332.x

10.1002/clc.4960090308

Leon‐Sotomayor LA, 1974, Cardiac migraine—report of twelve cases, Angiology, 9, 121

10.1111/j.1365-2796.1991.tb00472.x

10.1016/S0140-6736(94)91642-X

10.1159/000116756

10.1038/sj.bjp.0701509

10.1111/j.1476-5381.1996.tb15982.x

10.1046/j.1468-2982.2000.00009.x

10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N

10.1016/S0140-6736(00)02758-6

10.1212/WNL.45.12.2135

Thông tin
Thông tin xuất bản

Headache

Tập 44 Số 5

414-425

Thông tin tác giả